« Back to Record
Citation APA

de Cremoux, P., Resche-Rigon, M., Sotiriou, C., Groheux, D. D., Biard, L., Poirot, B., Bertheau, P., Teixeira, L., Lehmann-Che, J., Bouhidel, F. A., Merlet, P., & Espié, M. (2018). 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget, 9(23), 16343-16353. doi:10.18632/oncotarget.24674


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/270564

de Cremoux, P., Resche-Rigon, M., Sotiriou, C., Groheux, D. D., Biard, L., Poirot, B., Bertheau, P., Teixeira, L., Lehmann-Che, J., Bouhidel, F. A., Merlet, P., & Espié, M. (2018). 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget, 9(23), 16343-16353. doi:10.18632/oncotarget.24674